Cargando…
Heart Failure—Do We Need New Drugs or Have Them Already? A Case of Coenzyme Q10
Heart failure (HF) is a global epidemic that contributes to the deterioration of quality of life and its shortening in 1–3% of adult people in the world. Pharmacotherapy of HF should rely on highly effective drugs that improve prognosis and prolong life. Currently, the ESC guidelines from 2021 indic...
Autores principales: | Filipiak, Krzysztof J., Surma, Stanisław, Romańczyk, Monika, Okopień, Bogusław |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143244/ https://www.ncbi.nlm.nih.gov/pubmed/35621872 http://dx.doi.org/10.3390/jcdd9050161 |
Ejemplares similares
-
Colchicine — From rheumatology to the new kid on the block: Coronary syndromes and COVID-19
por: Surma, Stanisław, et al.
Publicado: (2023) -
Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
por: Surma, Stanisław, et al.
Publicado: (2021) -
Ranolazine - could an antianginal drug be used in stroke prevention?
por: Surma, Stanisław, et al.
Publicado: (2022) -
Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia
por: Surma, Stanisław, et al.
Publicado: (2023) -
Coffee and cardiac arrhythmias: Up-date review of the literature and clinical studies
por: Surma, Stanisław, et al.
Publicado: (2023)